118 related articles for article (PubMed ID: 3346401)
1. Delayed hypersensitivity to scopolamine in transdermal therapeutic systems.
van der Willigen AH; Oranje AP; Stolz E; van Joost T
J Am Acad Dermatol; 1988 Jan; 18(1 Pt 1):146-7. PubMed ID: 3346401
[No Abstract] [Full Text] [Related]
2. Allergic contact dermatitis caused by transdermal hyoscine.
Gordon CR; Shupak A; Doweck I; Spitzer O
BMJ; 1989 May; 298(6682):1220-1. PubMed ID: 2526675
[No Abstract] [Full Text] [Related]
3. A review of contact dermatitis associated with transdermal therapeutic systems.
Holdiness MR
Contact Dermatitis; 1989 Jan; 20(1):3-9. PubMed ID: 2492460
[TBL] [Abstract][Full Text] [Related]
4. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects.
Shupak A; Gordon CR; Spitzer O; Mendelowitz N; Melamed Y
Pharmatherapeutica; 1989; 5(6):365-70. PubMed ID: 2594820
[TBL] [Abstract][Full Text] [Related]
5. Adverse dermatologic reactions to transdermal drug delivery systems.
Hogan DJ; Maibach HI
J Am Acad Dermatol; 1990 May; 22(5 Pt 1):811-4. PubMed ID: 2112162
[TBL] [Abstract][Full Text] [Related]
6. Transdermal scopolamine withdrawal syndrome.
Feder RE
Clin Neuropharmacol; 1999; 22(2):120. PubMed ID: 10202610
[No Abstract] [Full Text] [Related]
7. Toxic psychosis from transdermal scopolamine in a child.
Sennhauser FH; Schwarz HP
Lancet; 1986 Nov; 2(8514):1033. PubMed ID: 2877187
[No Abstract] [Full Text] [Related]
8. Transdermal scopolamine intoxication in a child.
Klein BL; Ashenburg CA; Reed MD
Pediatr Emerg Care; 1985 Dec; 1(4):208-9. PubMed ID: 3842169
[No Abstract] [Full Text] [Related]
9. Side effects of transdermal scopolamine.
Wilkinson JA
J Emerg Med; 1987; 5(5):389-92. PubMed ID: 3668203
[TBL] [Abstract][Full Text] [Related]
10. Delayed hypersensitivity to scopolamine delivered by a transdermal device.
Trozak DJ
J Am Acad Dermatol; 1985 Aug; 13(2 Pt 1):247-51. PubMed ID: 2931457
[TBL] [Abstract][Full Text] [Related]
11. Unilateral mydriasis caused by transdermal scopolamine.
Rubin MM; Sadoff RS; Cozzi GM
Oral Surg Oral Med Oral Pathol; 1990 Nov; 70(5):569-70. PubMed ID: 2234876
[TBL] [Abstract][Full Text] [Related]
12. [Transdermal scopolamine patches and anisocoria].
Roquer JM; Vila A; Roure C
Med Clin (Barc); 1995 May; 104(17):677-8. PubMed ID: 7623499
[No Abstract] [Full Text] [Related]
13. Transdermal scopolamine as a cause of transient psychosis in two elderly patients.
Mego DM; Omori JM; Hanley JF
South Med J; 1988 Mar; 81(3):394-5. PubMed ID: 3347867
[TBL] [Abstract][Full Text] [Related]
14. Transdermal scopolamine-induced neurologic deficits in patients with cancer.
Friedberg MH; Glantz MJ
R I Med; 1994 May; 77(5):141-2. PubMed ID: 8019013
[No Abstract] [Full Text] [Related]
15. Visual side-effects from transdermal scopolamine (hyoscine).
Firth AY; Walker K
Dev Med Child Neurol; 2006 Feb; 48(2):137-8. PubMed ID: 16417670
[TBL] [Abstract][Full Text] [Related]
16. No causal relationship between transdermal scopolamine and seizures: methodologic lessons for pharmacoepidemiology.
Strom BL; Carson JL; Schinnar R; Snyder ES; Shaw M; Waiter SL
Clin Pharmacol Ther; 1991 Jul; 50(1):107-13. PubMed ID: 1855348
[TBL] [Abstract][Full Text] [Related]
17. Central anticholinergic syndrome in a pediatric patient following transdermal scopolamine patch placement.
Holland MS
Nurse Anesth; 1992 Sep; 3(3):121-4. PubMed ID: 1445954
[TBL] [Abstract][Full Text] [Related]
18. Transdermal scopolamine for hyperemesis gravidarum.
Sagraves R; Anderson DC
Clin Pharm; 1992 Oct; 11(10):830, 833. PubMed ID: 1341989
[No Abstract] [Full Text] [Related]
19. Skin hypersensitivity reactions to transdermal therapeutic systems--still an important clinical problem.
Jenerowicz D; Polańska A; Olek-Hrab K; Silny W
Ginekol Pol; 2012 Jan; 83(1):46-50. PubMed ID: 22384639
[TBL] [Abstract][Full Text] [Related]
20. Scopolamine withdrawal syndrome.
Saxena K; Saxena S
Postgrad Med; 1990 Jan; 87(1):63-6. PubMed ID: 2296571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
